Saum Zamani
Research Subjects
Research Interests
Saum Zamani has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Akhil Kotwal
Department of Radiation Oncology and Molecular Radiation Sciences; and
1 shared publication - Alexis Bennett
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center
1 shared publication - Alyza Skaist
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication - Chien-Fu Hung
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication - Eitan Halper-Stromberg
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center
1 shared publication - Hong Liang
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer
While radiation is an effective oncologic therapy, killing cancer by inducing DNA double-strand breaks (DSBs), it lacks specificity for neoplastic cells. We have previously adapted the CRISPR/Cas9 gene-editing technology as a cancer-specific treatment modality targeting somatic mutations in pancreatic cancer (PC). However, its tumoricidal potential remains unclear, especially in comparison with therapeutic doses of radiation. Here, we demonstrate that CRISPR/Cas9-induced DSBs are more cytotoxic in PCs than a comparable number of radiation-induced DSBs. We observed more than 90% tumor growth inhibition by targeting 9 sites with cancer-specific sgRNAs. Through both bioinformatics and cytogenetics analyses, we found that CRISPR/Cas9-induced DSBs triggered ongoing chromosomal rearrangements, with 87% of structural variants not directly produced from the initial CRISPR/Cas9-induced DSBs, and chromosomal instability peaking before cell death. By comparing the cytotoxicity of CRISPR/Cas9- and radiation-induced DSBs, we demonstrated that the number of DSBs required to achieve equitoxic effects was approximately 3 times higher for radiation than CRISPR/Cas9. Finally, we showed that PC cells that had survived CRISPR/Cas9 targeting retained susceptibility to subsequent CRISPR/Cas9-induced DSBs at different genomic sites with more than 87% growth inhibition. Together, our data support the therapeutic potential of CRISPR/Cas9 as an anticancer strategy. The CRISPR-Cas9 system can be adapted into a cancer killing strategy by inducing precise and unrecoverable DNA damage.
- 15 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Open AccessSimultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer
While radiation is an effective oncologic therapy, killing cancer by inducing DNA double-strand breaks (DSBs), it lacks specificity for neoplastic cells. We have previously adapted the CRISPR/Cas9 gene-editing technology as a cancer-specific treatment modality targeting somatic mutations in pancreatic cancer (PC). However, its tumoricidal potential remains unclear, especially in comparison with therapeutic doses of radiation. Here, we demonstrate that CRISPR/Cas9-induced DSBs are more cytotoxic in PCs than a comparable number of radiation-induced DSBs. We observed more than 90% tumor growth inhibition by targeting 9 sites with cancer-specific sgRNAs. Through both bioinformatics and cytogenetics analyses, we found that CRISPR/Cas9-induced DSBs triggered ongoing chromosomal rearrangements, with 87% of structural variants not directly produced from the initial CRISPR/Cas9-induced DSBs, and chromosomal instability peaking before cell death. By comparing the cytotoxicity of CRISPR/Cas9- and radiation-induced DSBs, we demonstrated that the number of DSBs required to achieve equitoxic effects was approximately 3 times higher for radiation than CRISPR/Cas9. Finally, we showed that PC cells that had survived CRISPR/Cas9 targeting retained susceptibility to subsequent CRISPR/Cas9-induced DSBs at different genomic sites with more than 87% growth inhibition. Together, our data support the therapeutic potential of CRISPR/Cas9 as an anticancer strategy. The CRISPR-Cas9 system can be adapted into a cancer killing strategy by inducing precise and unrecoverable DNA damage.